Methadone

Overview

Methadone is a synthetic diphenylpropylamine opioid, chemically distinct from both the phenanthrenes (morphine, the rigid five-ring opium alkaloid) and the phenylpiperidines (fentanyl, remifentanil, pethidine). It is a full agonist at the mu-opioid receptor, but — uniquely among the clinically used opioids — it also antagonises the NMDA (N-methyl-D-aspartate) receptor. This dual action is the single most exam-critical fact about the drug and underlies almost every distinctive clinical property [1][5].

Two pharmacological consequences shape methadone's place in practice. First, the NMDA antagonism gives it a niche where pure mu agonists fail — in neuropathic pain, in opioid-tolerant patients, and in countering opioid-induced hyperalgesia. Second, its very long and highly variable half-life makes it dangerous when dosed like a conventional opioid: accumulation, sedation and delayed respiratory depression are the classic pitfalls. Added to these is a characteristic cardiac risk — QT prolongation with torsades de pointes — that demands ECG monitoring [1][4].

Clinically, methadone has three domains of use: opioid maintenance therapy for opioid use disorder, chronic and cancer pain (especially with a neuropathic component or in the opioid-tolerant patient), and an emerging perioperative role as a single intraoperative dose providing prolonged postoperative analgesia [2][6].

Structure and stereochemistry

Methadone belongs to the diphenylpropylamine class. Its core is a diphenylmethane (a central carbon bearing two phenyl rings), substituted with a ketone and a dimethylamino group on a three-carbon chain. This places it apart from the two opioid structural families the exam emphasises [1]:

• NOT a phenanthrene — morphine, codeine and the natural/semi-synthetic opium alkaloids have the rigid five-ring phenanthrene skeleton. Methadone is fully synthetic and lacks this skeleton.
• NOT a phenylpiperidine — fentanyl, remifentanil, alfentanil, sufentanil and pethidine share the piperidine ring. Methadone has no piperidine ring. [1]

Methadone is supplied as a racemic mixture of two enantiomers, and the enantiomers carry different pharmacology — a fact that is the key to its dual action [1]:

• R-methadone (levomethadone, the active l-isomer) — the full mu-opioid agonist, responsible for analgesia and the classical opioid adverse effects, and roughly 8 to 50 times more potent than the S-enantiomer at the mu receptor.
• S-methadone (dextromethadone) — a non-competitive NMDA-receptor antagonist, the source of methadone's anti-hyperalgesic and anti-tolerance properties. The S-enantiomer also contributes to QT prolongation. [1]

[1]

Mechanism — mu agonism plus NMDA antagonism

R-methadone acts as a full agonist at the mu-opioid G-protein-coupled receptor. Receptor coupling to the inhibitory Gi/o protein inhibits adenylate cyclase (lowering intracellular cAMP), closes voltage-gated presynaptic calcium channels and opens inward-rectifying potassium channels; the neuron hyperpolarises and the presynaptic release of substance P, glutamate and CGRP in the dorsal horn falls. Descending inhibitory pathways from the periaqueductal grey and rostral ventromedial medulla are enhanced. The result is the classical mu-opioid profile — analgesia, sedation, miosis, dose-dependent respiratory depression, constipation and euphoria — qualitatively identical to morphine [1].

What sets methadone apart is that S-methadone also antagonises the NMDA receptor (non-competitive, open-channel blockade). This is unique among the clinically used opioids. NMDA-receptor signalling is central to central sensitisation, wind-up, opioid-induced hyperalgesia and the development of tolerance. By blocking NMDA, methadone [1][5]:

• reduces neuropathic pain signalling, where NMDA-mediated central sensitisation is prominent;
• retains analgesic efficacy in the opioid-tolerant patient, in whom pure mu agonists lose effect partly through NMDA-upregulated hyperalgesia;
• partly counteracts the development of opioid-induced hyperalgesia and tolerance. [1]

In addition, methadone is a weak inhibitor of serotonin and norepinephrine reuptake, analogous to (but weaker than) tramadol. This contributes a minor monoaminergic analgesic component and, clinically, the small risk of serotonin syndrome with other serotonergic agents [1].

[1]

Pharmacokinetics — the long, variable half-life

Methadone's pharmacokinetics are extraordinary and are the most examined aspect of the drug [1].

[1]

Absorption. Oral methadone is well and reliably absorbed. The high oral bioavailability (40 to 100 per cent) means the oral and parenteral doses are similar — a rarity among opioids (morphine's oral bioavailability is only about 25 to 30 per cent due to first-pass metabolism) [1].

Distribution and protein binding. The large volume of distribution (3 to 5 L/kg) and extensive tissue binding, combined with high plasma protein binding to alpha-1-acid glycoprotein (85 to 90 per cent), create a deep peripheral reservoir that releases methadone slowly back into the central compartment. This is the kinetic basis of the long half-life. Because AAG is an acute-phase reactant, the free (active) fraction fluctuates with illness, adding another source of variability [1].

Metabolism. Methadone is metabolised in the liver principally by CYP3A4 and CYP2B6 to metabolites that are inactive. Importantly, methadone is NOT a substrate for CYP2D6 — this distinguishes it from codeine and tramadol, whose analgesia depends on CYP2D6 activation, and it means CYP2D6 polymorphism does not affect methadone clearance. The absence of any active metabolite is clinically relevant: there is no opioid-active moiety that accumulates independently of the parent (unlike morphine's M6G or pethidine's neurotoxic normeperidine) [1].

Excretion. Metabolites and a small fraction of unchanged drug are excreted in urine and bile. Because of high protein binding and a large volume of distribution, methadone is not effectively removed by haemodialysis [1].

The defining feature: the half-life. Methadone's elimination half-life ranges from 8 to 59 hours (mean about 24). The variability between individuals is large and largely unpredictable, driven by genetic differences in CYP3A4/2B6 activity and by fluctuations in AAG. The practical implication is that steady state is reached only after many days of dosing, and any dose increase takes days to fully manifest. A patient who appears well on a given dose on day 2 may yet accumulate toxic levels by day 5. [1]

[1]

The analgesic duration versus half-life mismatch

The single most important clinical trap with methadone is the mismatch between its analgesic duration and its plasma half-life [1].

The analgesic duration of a single dose is only about 4 to 8 hours, whereas the plasma half-life is about 24 hours (range 8 to 59). This means that long after the analgesic effect of a dose has worn off and the next dose is due, most of the previously administered methadone is still in the body [1].

If methadone is dosed at the analgesic interval of every 4 to 8 hours, each new dose is added on top of drug that has barely been cleared. Over successive doses the plasma and effect-site concentrations creep upwards, producing the classic presentation of delayed accumulation toxicity — sedation and respiratory depression that appear 12 to 24 hours (or longer) after a dose regimen that initially seemed well tolerated [8]. This is fundamentally different from a drug like morphine, whose analgesic duration and half-life are broadly concordant, and it is the reason methadone dose escalation must be slow and cautious, with waiting periods of several days between increases to allow accumulation to declare itself.

[1]

The NMDA antagonism — the pharmacological advantage

The NMDA antagonism is methadone's key pharmacological advantage and the mechanistic reason for its distinctive clinical niches [1][5].

NMDA-receptor activation drives central sensitisation (wind-up), the amplification of nociceptive signalling in the dorsal horn that underlies neuropathic pain, opioid-induced hyperalgesia and the development of opioid tolerance. By non-competitively blocking the NMDA channel, S-methadone interrupts this process. The clinical consequences are threefold: [1]

1. Efficacy in neuropathic pain — where NMDA-mediated central sensitisation is prominent and where pure mu agonists are often disappointing.
2. Efficacy in the opioid-tolerant patient — who has become tolerant partly through NMDA-upregulated hyperalgesia, and in whom methadone can recover analgesia that morphine has lost.
3. Attenuation of opioid-induced hyperalgesia and tolerance — methadone partly opposes the very hyperalgesia that chronic opioid exposure produces. [1]

This is also why methadone's relative potency increases at higher baseline opioid doses: a patient taking large amounts of morphine has developed a degree of NMDA-mediated tolerance and hyperalgesia that methadone, by blocking NMDA, can partially overcome — so a smaller-than-expected methadone dose replaces a large morphine dose (see Conversion). [1]

Clinical uses — opioid maintenance therapy

The best-established use of methadone is as medication for opioid use disorder (MOUD), where it functions as a long-acting oral opioid that stabilises the patient, suppresses withdrawal and craving, and — at adequate doses — blocks the euphoria of illicit opioids [6][7].

The long half-life, which is a liability in acute dosing, is an asset here: it allows once-daily oral dosing for maintenance, with stable trough levels that prevent withdrawal between doses. Specialised treatment services are the appropriate setting. Recent evidence supports the effectiveness of dedicated substance-use disorder treatment services in delivering methadone maintenance, and identifies the importance of sleep-disordered breathing and respiratory symptoms in this population — a relevant perioperative consideration [6][7].

In the hospital setting, patients on maintenance methadone should have their usual dose continued to prevent withdrawal and destabilisation, and inpatient MOUD programmes are increasingly recognised as improving outcomes [6].

Clinical uses — chronic and cancer pain

Methadone has a defined role in chronic and cancer pain, particularly where the pain has a neuropathic component or where the patient is opioid-tolerant and conventional opioids are losing effect [1][5]. Its NMDA antagonism is the mechanistic basis for this niche.

In palliative care, methadone is often used as a second-line or rotation opioid when morphine or oxycodone produces inadequate analgesia or intolerable side effects, or when renal failure makes morphine unsuitable (methadone has no active renally-cleared metabolite and its clearance is hepatic). Guidance for palliative opioid therapy includes methadone among the options for rotation, while emphasising the complexity of conversion and the need for specialist input [5].

Perioperative and acute pain — the emerging role

Because of its unpredictable and very long half-life, methadone is NOT a first-line agent for opioid-naive perioperative analgesia, where titratability and predictable offset are paramount [1][8]. However, a body of evidence — principally the Murphy cardiac-surgery trials and a series of systematic reviews — has established an emerging role for a single intraoperative dose [2][3][9].

The technique exploits methadone's long half-life as an asset rather than a liability. A single intraoperative intravenous dose of 0.1 to 0.2 mg/kg at induction produces 24 to 48 hours of postoperative analgesia, reduces postoperative opioid (PCA morphine) consumption, lowers pain scores, and may reduce persistent postoperative pain [2][3]:

• Murphy 2015 (Anesthesiology) — a randomised double-blind trial in cardiac surgical patients showed that intraoperative methadone reduced postoperative opioid requirements and pain scores for 48 hours compared with fentanyl [2].
• Murphy 2020 (Anesthesiology) — the one-year secondary analysis showed that the intraoperative methadone group had lower pain scores and reduced opioid use extending well beyond the immediate perioperative period [3].
• Systematic reviews are formally evaluating the analgesic efficacy and, critically, the respiratory-depression risk of perioperative methadone across orthopaedic and other surgery [8][9].

The caveat, and the reason this remains a specialist technique, is the need for prolonged respiratory monitoring because of late accumulation toxicity. Recent protocols are explicitly designed to quantify this risk [8].

[1]

Equianalgesic dosing and conversion

Equianalgesic conversion to and from methadone is complex, non-linear and requires specialist input [1][5]. Four principles drive the difficulty:

• Incomplete cross-tolerance — when switching from another opioid to methadone, the existing tolerance does not fully transfer, so a naive 1-to-1 conversion overestimates the safe methadone dose and risks overdose.
• Variable half-life — because the half-life ranges so widely between individuals, the same milligram dose produces very different steady-state levels in different patients.
• Accumulation — the conversion must anticipate that levels will continue to rise over days, not hours.
• Non-linear potency — methadone's potency relative to morphine increases at higher baseline opioid doses, so a single equianalgesic ratio is not valid across all patients. This is the cardinal conversion fact. [1]

The morphine-to-methadone conversion ratio therefore varies with the starting morphine dose [5]:

[1]

This dose-dependent increase in relative potency reflects the progressive development of NMDA-mediated tolerance and hyperalgesia at high opioid doses, which methadone partially reverses [5].

For these reasons, methadone rotation is typically done by reducing the calculated equianalgesic dose substantially (often by 75 to 90 per cent to account for incomplete cross-tolerance), giving methadone as a fraction of the total, and cross-titrating slowly over days — reducing the old opioid while gradually increasing methadone, with close observation. The rule stands: methadone is not a first-line opioid for the opioid-naive patient, and conversion should be undertaken with specialist input [1][5].

QT prolongation and torsades de pointes

Methadone prolongs the QT interval by blocking the delayed rectifier potassium current (the hERG channel), and at sufficient exposure this can trigger polymorphic ventricular tachycardia — torsades de pointes [4]. This is a dose-dependent, channel-mediated effect rather than an idiosyncrasy; the S-enantiomer contributes disproportionately to the hERG block.

The risk rises with factors that either raise methadone exposure or independently prolong repolarisation [4]:

• High methadone doses — the risk rises meaningfully at higher daily doses (a common threshold for screening is above 100 mg per day).
• Co-administration of other QT-prolonging drugs — antiarrhythmics (amiodarone, sotalol, quinidine), antipsychotics (haloperidol, droperidol), macrolides (erythromycin, clarithromycin), fluoroquinolones, azole antifungals, and some antiemetics (ondansetron, droperidol).
• Hypokalaemia and hypomagnesaemia — which directly predispose to torsades.
• Hepatic dysfunction or CYP3A4 inhibition — which raise methadone levels.
• Structural heart disease, bradycardia and female sex — independent torsades risk factors. [1]

Because of this, an ECG is recommended before starting methadone and after dose escalation, particularly in patients with risk factors or at doses above 100 mg per day, and any electrolyte disturbance should be corrected [4].

Serotonin syndrome and drug interactions

In addition to NMDA antagonism, methadone is a weak inhibitor of serotonin and norepinephrine reuptake. In combination with other serotonergic agents — selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tramadol, pethidine and certain triptans — methadone can contribute to serotonin syndrome, characterised by autonomic instability, clonus, hyperreflexia, rigidity and agitation [1].

The full drug-interaction profile therefore spans three axes [1][4]:

• CYP3A4/2B6 metabolism — inducers (rifampicin, carbamazepine, phenytoin, barbiturates) lower methadone levels and can precipitate withdrawal; inhibitors (macrolides, azole antifungals, some antiretrovirals, grapefruit) raise levels and can precipitate overdose and respiratory depression.
• QT prolongation — additive with other hERG-blocking drugs (see above).
• Serotonergic effects — additive with SSRIs, SNRIs, MAOIs, tramadol and pethidine, risking serotonin syndrome. [1]

[1]

Adverse effects and accumulation risk

Methadone's adverse-effect profile combines the standard mu-opioid effects with its distinctive accumulation and cardiac risks [1][4]:

• Delayed respiratory depression — the cardinal risk of accumulation; it may appear 12 to 24 hours (or more) after starting or increasing the dose, when a regimen initially seemed well tolerated [8].
• Sedation and coma — accumulating levels progressively depress consciousness; sedation often precedes respiratory depression and is a clinical warning sign.
• QT prolongation and torsades de pointes — discussed above; an ECG is part of safe prescribing [4].
• Constipation, nausea, miosis, sweating, dry mouth — standard opioid effects.
• Serotonin syndrome — in combination with other serotonergic agents [1].
• Tolerance, physical dependence and withdrawal — methadone withdrawal is prolonged but milder than morphine withdrawal, reflecting the drug's slow clearance; symptoms emerge more slowly and last longer but are less intense.
• No histamine release — unlike morphine, methadone does not release histamine, giving it cardiovascular stability comparable to fentanyl.

Overdose and reversal

Overdose with respiratory depression is reversed by naloxone, the competitive mu-opioid antagonist. Naloxone displaces methadone from the mu receptor and rapidly restores ventilation (IV onset 1 to 2 minutes). It is titrated to the respiratory rate and oxygenation, not to full alertness, to avoid precipitating severe pain, acute withdrawal and a catecholamine surge — 40 to 80 microgram IV increments every 2 to 3 minutes until the respiratory rate is adequate [1].

Because methadone's half-life (8 to 59 hours) far exceeds naloxone's (30 to 90 minutes), renarcotisation is expected once the naloxone wears off. Prolonged monitoring, repeat boluses or a naloxone infusion (for example two-thirds of the effective bolus dose per hour) are required to prevent resedation and late respiratory arrest [1][8].

Comparison with other opioids

Methadone differs from the other commonly examined opioids on several axes [1][2][4]:

[1]

Red flags

[1]

References

1. [1]Kreutzwiser D, Tawfic HA, Szeto JG. Methadone for Pain Management: A Pharmacotherapeutic Review CNS Drugs, 2020.PMID 32564328
2. [2]Murphy GS, Sherwani SS, Szokol JW, et al. Intraoperative Methadone for the Prevention of Postoperative Pain: A Randomized, Double-blinded Clinical Trial in Cardiac Surgical Patients Anesthesiology, 2015.PMID 25837528
3. [3]Murphy GS, Avram MJ, Greenberg SB, et al. Postoperative Pain and Analgesic Requirements in the First Year after Intraoperative Methadone for Complex Spine and Cardiac Surgery Anesthesiology, 2020.PMID 31939849
4. [4]El Sherbini A, Scherer LD, Lee JM, Tisdale JE. Opioids-induced inhibition of HERG ion channels and sudden cardiac death, a systematic review of current literature Trends Cardiovasc Med, 2024.PMID 37015297
5. [5]Mercadante S, Caraceni A, Hagen N, et al. Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review Palliat Med, 2011.PMID 21708857
6. [6]Miller M, et al. How are we going to be able to pull that off?: staff perspectives on the early implementation of mobile medication units in New York State Addict Sci Clin Pract, 2026.PMID 42343429
7. [7]Palix D, et al. Prevalence of sleep-related symptoms in patients receiving methadone maintenance treatment: a systematic review and meta-analysis Addict Sci Clin Pract, 2026.PMID 42321898
8. [8]Nunez-Rodriguez E, et al. Evaluating respiratory depression after methadone administration in surgical patients: protocol for a systematic review and meta-analysis BMJ Open, 2025.PMID 40447426
9. [9]Evaldsson BB, et al. Analgesic efficacy of peri-operative methadone in orthopaedic surgery: protocol for a systematic review of randomised controlled trials BMJ Open, 2026.PMID 41724506